OPTN

OptiNose, Inc.

1.19 USD
-0.04 (-3.64%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

OptiNose, Inc. stock is down -3.25% since 30 days ago. The next earnings date is Mar 5, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 42.86% of the previous 6 December’s closed higher than November.

About OptiNose, Inc.

OptiNose, Inc. focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically-acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps. Onzetra Xsail, a powder EDS device, is in Phase IIIb clinical trial.